Everest Medicines Completes Enrollment of Phase 3 Clinical Trial of Xeravaa?? (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections in China

Top-line data from China Phase 3 trial expected in the fourth quarter of 2020

SHANGHAI, China, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that it completed patient enrollment for its Phase 3 clinical trial of eravacycline (marketed as Xeravaa?? in the US and EU) for the treatment of complicated intra-abdominal infections (cIAI) in patients in China.Xerava is a novel, fully synthetic, broad-spectrum parenteral antibiotic of the tetracycline class. In two previous global pivotal studies, Xerava was well tolerated in people with cIAI and demonstrated statistical non-inferiority to two widely used comparators a?? ertapenem and meropenem. These two studies led to Xeravaa??s approvals in US, EU and Singapore. Top-line results from this China trial are expected in the fourth quarter of 2020 and plan to support Everest Medicinesa?? New Drug Application filing in China.a??Our first China Phase 3 trial is an important milestone for Everest Medicines and reinforces our commitment to accelerate the development and commercialization of our broad pipeline of novel drug candidates to address unmet medical needs in Greater China and other parts of Asia,a?? said Sunny Zhu, Chief Medical Officer for Infectious Diseases at Everest Medicines. a??Xerava represents an important potential new treatment option for the management of complicated infections, especially among drug resistant pathogens.a??a??As we work to complete this registrational trial and move towards potential approval in China, we are grateful to the many researchers, healthcare providers and patients who have participated in the study, even throughout the COVID-19 pandemic, enabling us to rapidly advance important medical innovations for patients in even the most difficult environments,a?? said Kerry Blanchard, MD, PhD, Chief Executive Officer of Everest Medicines.Under the licensing agreement with Tetraphase Pharmaceuticals, Everest Medicines has exclusive rights to develop and commercialize Xerava in Greater China, South Korea, and the key markets of South East Asia, including Indonesia, Malaysia, Philippines, Thailand, Singapore and Vietnam. Xerava is approved for the treatment of cIAI in adults by the Health Science Authority (HSA) in Singapore in April 2020. Xerava is currently approved for the treatment of cIAI in the US and EU.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Апрель 2021    »